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A simple stability-indicating RP-HPLC/UV method was validated for determination of beclomethasone 
dipropionate (BD) in nanocapsule suspensions. Chromatographic conditions consisted of a RP C18column 
(250 mm x 4.60 mm, 5 µm, 110 Å), using methanol and water (85:15 v/v) as mobile phase at 1.0 mL/
min with UV detection at 254 nm. The calibration curve was found to be linear in the concentration 
range of 5.0-25.0 µg/mL with a correlation coefficient > 0.999. Precision was demonstrated by a relative 
standard deviation lower than 2.0%. Accuracy was assessed by the recovery test of BD from nanocapsules 
(98.03% to 100.35%). Specificity showed no interference from the components of nanocapsules or from 
the degradation products derived from acid, basic and photolytic conditions. In conclusion, the method 
is suitable to be applied to assay BD in bulk drug and in nanocapsules, and it can be employed to study 
stability and degradation kinetics.
Uniterms: High performance liquid chromatography/reverse phase/quantitative analysis. Beclomethasone 
dipropionate/determination. Nanocapsule/suspensions. Nanoparticles.
Um método simples de CLAE-FR/UV indicativo de estabilidade foi validado para a determinação do 
dipropionato de beclometasona (BD) em suspensões de nanocápsulas. As condições cromatográficas 
foram: coluna C18 fase reversa (250 mm x 4,60 mm, 5 µm, 110 Å), usando como fase móvel metanol e 
água (85:15 v/v) a 1,0 mL/min, com detecção UV a 254 nm. A curva de calibração foi linear no intervalo 
de 5,0-25,0 µg/mL com coeficiente de correlação >0,999. A precisão foi demonstrada por um desvio 
padrão relativo menor que 2,0%. A exatidão foi avaliada pelo teste de recuperação do BD a partir das 
nanocápsulas (98,03% a 100,35%). O teste de especificidade não mostrou interferência dos componentes 
das nanocápsulas e nem dos produtos de degradação derivados de condições ácidas, básicas e fotolíticas. 
Em conclusão, o método é adequado para ser aplicado na avaliação do BD puro e em nanocápsulas e 
pode ser empregado para o estudo de estabilidade e degradação cinética.
Unitermos: Cromatografia líquida de alta eficiência/fase reversa/análise quantitativa. Dipropionato de 
beclometasona/determinação. Nanocápsulas/suspensões. Nanopartículas.
INTRODUCTION
Beclomethasone dipropionate (BD; C38H28ClO7; 
MW: 521.0 Da) (Figure 1), a synthetic chlorinated 
glucocorticoid diester, is a well-established anti-
inflammatory agent used in the treatment of asthma 
(Vidgren et al., 1995). BD is characterized by a white or 
almost white crystalline powder, presenting pKa of 13.6 
and melting range between 117-120 °C (Wilcox, Avery, 
1973; Brogden et al., 1984; Barnes, 2010; ECP, 2010). 
The mechanism of action of BD occurs at cellular nucleus 
level by interacting with DNA and hence stimulating or 
suppressing gene transcription. This drug can act as a 
transcription factor, altering the expression of target genes 
in response to a specific hormonal signal (De Kloet et al., 
1993).
BD has been proven to be effective when used by 
inhalation in asthmatic patients compared to placebo. 
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In this way, the therapeutic effect of conventional doses 
of inhaled BD is attributed to its direct action on the 
respiratory tract (Cole et al., 1999). However, BD is 
a highly hydrophobic drug, and it thus presents slow 
dissolution rate within airways and rapid mucociliary 
clearance, resulting on a relative short local duration 
of action following administration with a consequent 
reduction in its therapeutic effect (Jacobs, Müller, 2002; 
Sakagami et al., 2002). Following powder aerosol 
administration, BD is partially removed from its 
primary site of action, the lower airways, by mucociliary 
clearance prior to dissolution and absorption, and 
eventually, swallowed into the gastrointestinal tract 
(Hochhaus et al., 1997). Therefore, BD entrapment 
within biocompatible and biodegradable nanocarriers is 
a promising approach to improve therapeutic efficacy, 
reduce the risk of side effects by prolonging BD retention 
time in the lung and achieve controlled or targeted drug 
delivery (Helle et al., 2008). 
Nanocapsules  are  col lo ida l  drug car r iers 
characterized by a lipophilic core surrounded by a 
polymeric layer, in which the drug can be dissolved 
in the oily core and/or adsorbed on the polymeric wall 
(Schaffazick et al., 2003). The advantages of using 
such colloidal carriers include: potential to increase the 
bioavailability of poorly water-soluble drugs, ability 
to control the rate and/or the site of drug release and 
possibility to improve drug stability related to enzymatic, 
immunological or chemical/photochemical degradation, 
among others (Couvreur, Vauthier, 2006). In this way, 
experiments are being conducted in our laboratory 
in order to formulate BD-loaded biodegradable 
nanocapsules. At the same time, it is necessary to work 
with a validated analytical technique for assaying BD in 
these formulations.
A literature review indicated few HPLC methods 
to determine BD in pharmaceutical formulations. BD is 
officially listed in the British and in the US Pharmacopeias. 
In the first one, a laborious method was described using 
elution by gradient, elevated temperature, and presenting 
retention time of 25 min (British Pharmacopeia, 2010). 
In its turn, US Pharmacopeia (USP, 2009) reports a 
simpler HPLC method with a mobile phase constituted 
by acetonitrile and water elution at room temperature. 
Retention time is approximately 6 min. In the open 
literature, validated analytical methods for the analysis 
of BD in bulk drug and pharmaceutical formulations were 
not found. In relation to the analysis of BD in biological 
fluids, Foe and co-workers (Foe et al., 2000) compared 
the kinetic disposition and metabolism of BD and its 
monopropionate ester in human lung homogenates and 
plasma using a HPLC method with an isocratic mobile 
phase. UV detection was performed at 242 nm. According 
to Girault and co-workers, low levels of corticosteroids 
cannot be accurately measured with conventional HPLC 
methods due to lack of sensitivity. For this reason, HPLC 
coupled to mass spectrometry has been used for BD 
quantification in complex biological matrices (Girault et 
al., 1991; Taylor, Grebe, Sing, 2004). 
According to the stability guideline of the 
International Conference on Harmonization (ICH, 2003), 
stress testing of a drug substance can be carried out 
to elucidate its inherent stability characteristics under 
hydrolytic, oxidative and photolytic conditions. 
Taking all of this into account, in the present study, 
a simple reverse-phase HPLC method with UV detection 
was validated for quantifying BD in nanocapsules, as 
well as to study forced degradation of the drug under 
stress conditions. The experiments were performed in 
accordance with ICH guideline parameters (ICH, 1996; 
ICH, 2003; ICH, 2005). It is relevant to mention that 
the method developed in our work is easy, low cost and 
employ few raw materials to quantify BD in nanocapsules. 
MATERIAL AND METHODS
Material
Beclomethasone dipropionate  (97% w/w) 
was obtained from Henrifarma (São Paulo, Brazil). 
Poly (ε-caprolactone) (PCL) and Span 80® (sorbitan 
monooleate) were acquired from Sigma Aldrich (São 
Paulo, Brazil). Tween 80® (polysorbate 80) was purchased 
from Delaware (Porto Alegre, Brazil). Sweet almond 
oil was kindly donated by Campestre (São Bernardo do 
Campo, Brazil). HPLC-grade methanol was purchased 
from Tedia (São Paulo, Brazil). Ultrapure water was 
obtained from a Milli-Q® Plus apparatus (Millipore, 
Billerica, USA). All other solvents and reagents were of 
analytical grade and used as received.
FIGURE 1 - Chemical structure of beclomethasone dipropionate.
Stability-indicating RP-HPLC method for determination of beclomethasone dipropionate in nanocapsule suspensions 805
Apparatus and chromatographic conditions
All the experiments were performed on a Shimadzu 
LC-10A HPLC system (Kyoto, Japan) fitted with a LC-10 
ADVP pump, an UV-VIS SPD-10AVP detector, a SCL-
10AVP system controller, and a Rheodyne valve sample 
manual injector with 50 µL loop. For separations, a RP C18 
Phenomenex column (250 mm x 4.60 mm, 5 µm particle 
size, 110 Å pore diameter) was used at room temperature 
as well as a mobile phase consisting of methanol and 
water (85:15 v/v) at isocratic flow rate (1.0 mL/min). 
The injection volume was 50 µL and the detection was 
monitored at a wavelength of 254 nm. The peak areas were 
automatically integrated by the Class VP solution software 
program. In order to protect the analytical column, a guard 
column was used (Security Guard C18 4 x 3.0 mm).
Preparation of nanocapsule suspensions
BD-loaded nanocapsule suspensions were prepared 
by interfacial deposition of preformed polymers (Fessi, 
Puisieux, Devissaguet, 1988). An organic solution 
consisting of acetone, BD (0.5 mg/mL), PCL (1 mg/mL), 
sorbitan monooleate (0.77 mg /mL) and almond oil (3 
%) was added into an aqueous solution of polysorbate 
80 (0.77 mg/mL) under moderate magnetic stirring at 
40 °C. After 10 min, the acetone was eliminated and the 
water was concentrated under reduced pressure to achieve 
0.5 mg/mL of BD. The sample was named NC-BD. For 
comparison purposes, a blank formulation was prepared 
while omitting the drug (NC-B). 
Preparation of standard and sample solutions
A stock standard solution (0.5 mg/mL) of BD 
was prepared by accurately weighing 0.0125 g of drug, 
transferring to 25 mL volumetric flask and making up 
to volume with methanol. For BD quantification in the 
nanocapsules and evaluation of the validation parameters, 
the suspensions were diluted with methanol, sonicated for 
10 min and then subjected to centrifugation for 20 min 
to extract the drug. All solutions were filtered through 
a regenerated cellulose membrane (pore size 0.45 µm) 
before HPLC injection (n=3). 
Method development
Detection wavelength for the HPLC study was 
selected at 254 nm. The chromatographic conditions were 
optimized for resolution of the peak of BD and degradation 
products under each forced degradation condition by 
varying the proportion of methanol-water in the mobile 
phase. Samples of different stress conditions were used 
to optimize the chromatographic conditions for resolving 
BD and all the degradation products in a single run. An 
appropriate blank was injected before the analysis of 
all forced degradation samples. The method was then 
validated and applied for the determination of BD in 
nanocapsule suspensions. 
Method validation
Validation studies were conducted using the 
optimized assay conditions based on the principles of 
validation described in the ICH guidelines (ICH, 2005).
The method was validated for specificity, linearity, limit 
of detection (LOD), limit of quantitation (LOQ), accuracy, 
precision, and robustness.
Specificity was determined by analyzing the 
chromatograms of unloaded nanocapsule suspensions 
(blank nanocapsules) in comparison with those obtained 
for BD-loaded nanocapsules, in order to confirm that 
none of the excipients interfere with the quantitation of 
the drug. Peaks due to degraded products and excipients 
were examined.
Linearity test solutions for the assay method were 
prepared from BD stock solutions at five concentration 
levels (5.0, 10.0, 15.0, 20.0, and 25.0 μg/mL). The peak 
area versus concentration data was performed by least-
squares linear regression analysis. The calibration graph 
was obtained by plotting the peak areas of the standard 
solutions against standard concentrations. The linearity 
test was performed for 3 consecutive days in the same 
concentration range for the assay method. The solutions 
were injected in triplicate into the HPLC column keeping 
the injection volume constant (50 µL), and chromatograms 
were recorded. The relative standard deviation (RSD %) 
value for the slope and Y-intercept of the calibration curve 
were calculated.
LOD and LOQ were calculated based on the 
standard deviation of the response (δ) and the slope (S) of 
the calibration curve and were expressed as 3.3 δ/S and 
10 δ/S, for LOD and LOQ, respectively.
The accuracy of the analytical method was 
investigated by spiking blank nanocapsules with known 
concentrations of the stock solution to achieve final 
theoretical drug concentrations of 7.5, 12.5 and 17.5 µg/
mL. The analyses were performed in triplicate on three 
different days.
The precision of the assay method was determined 
in two levels: repeatability (intraday precision) and 
intermediate precision (interday precision). Six samples 
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of nanocapsules (15µg/mL) were assessed on the same 
day in order to evaluate the repeatability of the method and 
on two different days in order to determine intermediate 
precision. Results were reported in terms of relative 
standard deviation (RSD %).
To determine the robustness of the method, 
experimental conditions were purposely altered to check 
the reproducibility of the method. Robustness was 
evaluated by analyzing drug content of the nanocapsules 
with small variations in flow rate (0.9 and 1.1 mL/
min) and composition of the mobile phase (80:20 and 
90:10 methanol/water, v/v). Samples were evaluated in 
triplicate for each variation of the method conditions. 
Chromatograms were recorded and compared with the 
chromatographic conditions mentioned earlier. 
Forced degradation studies were also carried out in 
order to provide some information about drug stability 
and specificity of the proposed method. The standard 
solution of BD was subject to accelerated degradation 
by acid, basic and photolytic conditions. To study the 
acid degradation, 6.25 mL of the stock solution (1.0 mg/
mL of BD) was diluted in a 25 mL volumetric flask with 
0.1 mol/L HCl. This solution was maintained at room 
temperature and protected from light for 1 h. After the 
reaction time, the solution was neutralized with 0.1 mol/L 
NaOH. The solution was diluted with methanol to achieve 
a final concentration of 15 μg/mL before injection into the 
HPLC system. The same procedure was adopted for the 
alkaline degradation, except by the fact that 0.1 mol/L HCl 
was replaced by 0.1 mol/LNaOH in sample preparation. 
For photodegradation, 1.5 mL of BD methanolic solution 
(0.5 mg/mL of BD; BD-MS) was placed in a plastic cuvette 
and subsequently exposed to UV radiation (Phillips TUV 
lamp–254 nm, 30 W) for 6 h in a mirrored chamber (1 m x 
25 cm x 25 cm), at a fixed distance. At predetermined times 
(0, 1, 2, 3, 4 and 5 h) of exposure to light, 300 µL of the 
samples were withdrawn and diluted with methanol (final 
concentration of 15 μg/mL of BD) in order to quantify 
the remaining BD according to the method previously 
described. In order to refute the hypothesis of thermal 
degradation, a cuvette containing BD-MS was covered by 
aluminum paper and was evaluated in the same way. The 
degradation rate kinetics of BD was determined and the 
best fit observed indicates the reaction order. The kinetic 
equations used were: zero order (C=C0-kt), first order 
(lnC=lnC0-kt) and second order equation (1/C=1/C0+kt).
Evaluation of encapsulation efficiency
Encapsulation efficiency was estimated by 
the ultrafiltration-centrifugation technique using 
Amicon Ultra® 10,000 MW devices (Millipore). After 
centrifugation at 2200 x g for 10 min, free BD was assayed 
in the ultrafiltrate. The encapsulation efficiency was 
calculated as the difference between the total and the free 
drug concentrations, as follows:
RESULTS AND DISCUSSION
Optimization of chromatographic conditions
Viewing to establish the chromatographic conditions, 
preliminary tests were carried out in order to select the 
detection wavelength and the mobile phase composition. 
The organic solvent chosen to compose the mobile 
phase was methanol because it is more cost-effective 
than acetonitrile and it is the solvent used to prepare 
the standard and sample solutions. Initial trials were 
conducted with mixtures of methanol and ultrapure water 
in the following proportions: 70:30, 85:15 and 80:20 v/v. 
The mobile phases were tested at flow rates of 0.8, 1.0 and 
1.2 mL/min. With the aid of a photodiode array detector, the 
wavelength selected was 254 nm, which is in accordance 
with USP and British Pharmacopoeias. Considering 
retention time, peak symmetry, peak selectivity and peak 
width, the mobile phase of methanol and water (85:15, v/v) 
at 1.0 mL/min was considered satisfactory (theoretical 
plates = 5829 and tail factor = 1.1). Retention time was 
5.9 min (Figure 2 a).
Method validation
Specificity was evaluated for the influence of the 
formulation components, as well as for the interference 
of possible degradation products in the assay of BD. By 
comparing the both chromatograms presented in Figure 
2, it is possible to conclude that there is no interference 
from the components of nanocapsules in the drug peak. 
Moreover, the photodiode array detector showed that 
the BD peak was free from interferents (purity index > 
0.9999).
As for the linearity of the method, there was a 
linear relationship between peak area and concentration 
of BD in the concentration range of 5.0-25.0 µg/mL. 
The linear equation obtained by the least-square method 
was y = 56798x + 6295.1 and showed an adequate 
correlation coefficient (r = 0.9993). The validity of the 
assay was verified by analysis of variance (ANOVA), 
which confirmed that the regression equation was linear 
(Fcalculated = 1793.3864 >Fcritical = 4.96; p < 0.05) with 
no linearity deviation (Fcalculated = 0.7657<Fcritical = 3.71; 
p < 0.05).
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The accuracy of the method, evaluated by a recovery 
study, presented average recoveries for the three levels 
of concentration ranging from 98% to 101% (Table I). 
Regarding precision, the results of repeatability and 
intermediate precision showed RSD values lower than 
2%. Thus, the proposed analytical method was considered 
accurate and precise.
Regarding LOD and LOQ, the lowest concentrations 
assayed with acceptable precision and accuracy were 
0.16 μg/mL and 0.54 μg/mL, respectively, meaning that 
the method is sensitive enough to detect and quantitate BD 
in the concentration range of 5.0-25.0 µg/mL.
Concerning the evaluation of robustness, the results 
showed RSD values lower than 2%, which indicates 
that changes in the proportion of the mobile phase, as 
well as variations in the flow rate, did not affect the 
assay of BD in the nanocapsule suspensions (Table II). 
Minor variations in the retention time were observed, as 
expected, without compromising the evaluation of drug 
concentration.
In relation to the presence of degradation products, 
forced degradation studies showed different results 
depending on the stress conditions employed. In alkaline 
medium, there was significant degradation of BD, 
(approximately 99%), with one major additional peak 
detected at 3.6 min (Figure 3a). On the other hand, after 
exposure to 0.1 mol/L HCl, approximately 55% of BD 
was degraded (Figure 3b). Chen and co-workers reported 
the formation of an enol aldehyde from BD and other 
corticosteroids under acid conditions (Chen et al., 2009). 
However, the reaction conditions were not the same 
employed in our study. In that work, the enol aldehyde 
was generated from concentrated sulfuric acid, which 
was responsible for the β-elimination of water from the 
side chain of corticosteroid (Mattox rearrangement), and 
under alkaline conditions (1.0 N NaOH), there was no 
degradation of BD.





Recovery (%) RSD** (%)
Accuracy
Low 7.5 7.41 ± 0.19 98.73 2.61
Medium 12.6 12.22 ± 0.22 98.03 1.36
High 17.5 17.56 ± 0.10 100.35 0.58
Repeatability and intermediate precision
Day 1 (n=6) 15.00 14.86 ± 0.21 99.06 1.43
Day 2 (n=6) 15.00 15.27 ± 0.14 101.85 0.96
Mean ± SD 15.00 15.06 ± 0.29 99.06 1.97
*SD= Standard Deviation **RSD= Relative Standard Deviation.
FIGURE 2 - Chromatograms of standard solution (a), blank 
nanocapsules (b), beclomethasone dipropionate-loaded 
nanocapsules (c).
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TABLE II - Robustness data for beclomethasone dipropionate analysis (n=3)
Drug content (%) RSD* (%) Retention time (min)
Optimum conditions
     85:15 MeOH:Water; 1.00 mL/min 99.78 0.76 5.9
Mobile phase
     90:10MeOH:Water 100.69 0.78 4.2
     80:20MeOH:Water 99.78 0.28 5.4
Flow rate
     0.90 mL/min 100.27 1.97 5.1
     1.10 mL/min 100.28 0.73 6.3
*RSD= Relative Standard Deviation.
FIGURE 3 - Chromatograms obtained after one hour of BD 
exposure under alkaline conditions 0.1 mol/L NaOH (a) and 
under acid conditions 0.1 mol/L HCl (b).
Under photolytic conditions, there were decreases in 
the BD concentration of the methanolic solution (Figure 
4a). No additional peaks appeared in the chromatograms, 
indicating that the degradation products were not detected 
under the developed experimental conditions.
Aiming at elucidating the kinetics of photodegradation 
of BD from solution, the experimental data were fitted to 
zero, first and second order equations. The plots showed in 
Figure 4 indicated that the photodegradation process of BD 
in methanolic solution followed a zero order kinetic with 
FIGURE 4 - Plots of concentration (a)-zero-order reaction, 
log of concentration (b)-first-order reaction, and reciprocal 
of concentration (c)-second-order reaction of BD remaining 
versus time.
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a rate constant of 18.072 h-1. In this case, the degradation 
of BD does not depend on drug concentration.
Method application
In order to show the applicability of the validated 
method, the drug content and the encapsulation efficiency 
of BD-loaded nanocapsules were determined. The 
experimental concentration of the drug in the formulation 
was according to its theoretical concentration (0.5 mg/mL) 
with a low RSD value from the triplicate analysis 
(0.51±0.01%). As regards the rate of the drug associated 
with the polymeric nanocapsules, encapsulation efficiency 
was 99.37%, which can be explained by the lipophilic 
nature of this drug. Therefore, the validated method was 
successfully applied to the assay of BD in nanocapsule 
suspensions and can be considered an important tool in the 
quality control of these promising formulations. 
CONCLUSIONS
The developed and validated RP-HPLC method 
proved to be specific, linear, accurate, precise, and 
robust for the rapid determination of BD in polymeric 
nanocapsule suspensions, and it can be applied to study 
the stability and degradation kinetics of the drug. 
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